Antisense & RNAi therapeutics are novel class of drugs that can selectively modulate the production of disease-causing proteins.Theyhelp in preventing or treating a range of clinical conditions such as cancer,cardiovascular diseases, infectious diseases and genetic disorders. The growing demand for personalized medicines worldwide is driving the adoption of these therapeutics that can specifically target a patient's genetic abnormalities. The global Antisense & RNAi Therapeutics Market is estimated to be valued at US$ 6.38 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing adoption of personalized medicine worldwide is one of the key trends driving the growth of the antisense & RNAi therapeutics market. Personalized medicine involves tailoring medical treatment to an individual based on their genetic makeup and disease profile. It helps provide targeted treatment by developing drugs that can precisely modulate the expression of genes causing diseases. As antisense & RNAi therapeutics can specifically control gene expression at the RNA level, they are increasingly being used to develop personalized treatment options. The success of some clinically approved antisense & RNAi drugs has demonstrated their potential for precision medicine, fueling increased R&D and adoption of these novel therapeutics over the forecast period.
Segment Analysis
The global Antisense & RNAi Therapeutics market is dominated by cancer which accounts for around 45% of the market share. Cancer sub-segment dominates the overall market as antisense & RNAi therapeutics have shown promising results in cancer treatment by selectively targeting cancer causing genes.
Key Takeaways
The global Antisense & RNAi Therapeutics market demand is expected to witness high growth over the forecast period of 2024 to 2031.
Regional analysis:
North America region currently dominates the global market due to availability of advanced healthcare infrastructure and presence of key players in the region. However, Asia Pacific region is expected to witness fastest growth over the forecast period owing rising healthcare expenditure, increasing research & development activities for developing novel drugs and presence of large patient pool in the region.
Key players
operating in the global Antisense & RNAi Therapeutics market are Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc., Bio-Path Holdings Inc., Percheron Therapeutics Limited, GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc. and Arbutus Biopharma. Ionis Pharmaceuticals is the leading player owing to its strong product portfolio and pipeline molecules in clinical trials.
Get more insights on this topic: https://www.ukwebwire.com/global-antisense-rnai-therapeutics-market-industry-insightstrendsglobal-antisense-rnai-therapeutics-market/
Explore more information on this topic, Please visit: https://captionssky.com/footwear-sole-materials-an-analysis-of-modern-trends-and-future-outlook/
The new report by Expert Market Research titled, ‘Global Antisense and RNAi Therapeutics Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global antisense and RNAi therapeutics market, assessing the market based on its segments like end-product forms, equipment types, and applications.
The sample report shall be delivered to you within 24 hours.Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/antisense-and-rnai-therapeutics-market/requestsampleThe key highlights of the report include:Market Overview (2016-2026)Forecast CAGR (2021-2026): 8.5%Explore the full report with the table of contents@ https://www.expertmarketresearch.com/reports/antisense-and-rnai-therapeutics-marketIndustry Definition and Major SegmentsSpecific and highly effective gene silencing is possible due to antisense and RNAi therapeutics.
Oncology, cardiovascular disease, respiratory disorders, renal disease, neurodegenerative disorders, genetic disorders, infectious diseases, and other conditions are all treated with it.The Antisense and RNAi therapeutics industry can be divided based on:TechnologyRNA InterferenceSiRNAMiRNAAntisense RNARoute of AdministrationPulmonary DeliveryIntravenous InjectionsIntra-dermal InjectionsIntraperitoneal InjectionsTopical DeliveryMarket TrendThe global antisense and RNAi therapeutics industry is propelled by a deep understanding of gene function for disease management via the use of malfunctioning genes and the control of their gene expression.
Various collaborations between pharmaceutical companies and contract research organisations working to improve drug delivery are also driving the market.The global antisense and RNAi therapeutics market is being driven by the rising prevalence of infectious diseases and neurodegenerative disorders.
Nanocarriers have been shown to improve bioavailability, transporting limits of siRNA payload, and providing high cooperation with target cells.However, stringent regulations, a lengthy product approval process, high development costs, and a relatively small number of patients are just a few of the factors that contribute to the high cost of RNA interference drugs, which is expected to slow the market growth of antisense and RNAi therapeutics in the coming years.Key Market PlayersThe major players within the market are OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceuticals, Benitec Biopharma Ltd, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Antisense Therapeutics Ltd. and others.
The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of those market players.Read More Reports:-Global Sodium Monochloro Acetate Market: https://www.expertmarketresearch.com/reports/sodium-monochloro-acetate-marketGlobal Epigenetics Market: https://www.expertmarketresearch.com/reports/epigenetics-marketGlobal Digital Therapeutics Market: https://www.expertmarketresearch.com/reports/digital-therapeutics-marketGlobal Coco Coir Market: https://www.expertmarketresearch.com/reports/coco-coir-marketGlobal Metal Finishing Market: https://www.expertmarketresearch.com/reports/metal-finishing-marketGlobal Probiotic Supplements Market: https://www.expertmarketresearch.com/reports/probiotic-supplements-marketGlobal Styrene Market: https://www.expertmarketresearch.com/reports/styrene-marketGlobal Brain Computer Interface Market: https://www.expertmarketresearch.com/reports/brain-computer-interface-marketGlobal Wireless Microphone Market: https://www.expertmarketresearch.com/reports/wireless-microphone-marketGlobal Sodium Chlorite Market: https://www.expertmarketresearch.com/reports/sodium-chlorite-marketNote 2: As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours.
San Francisco, CA - Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025.
RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts.
Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell.
The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.
Request a PDF Sample @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come.
However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years.
Antisense & RNAi Therapeutics Global Market Report 2021 by The Business Research Company is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact – both negative and positive – of COVID-19 on the antisense & RNAi therapeutics industry gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
This includes revised market numbers according to the effects of the coronavirus and the expected antisense & RNAi therapeutics market growth numbers 2021-2030.
View Complete Report:https://www.thebusinessresearchcompany.com/report/antisense-and-RNAi-therapeutics-market-global-report-2020-30-covid-19-growth-and-change The Antisense & RNAi Therapeutics Global Market Report 2020-30 by The Business Research Company provides an in-depth analysis of the global antisense & RNAi therapeutics market and covers both the historic period, 2015 to 2020, and the forecast period, 2020 to 2030.
The report evaluates the market and major economies across the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.The Antisense & RNAi Therapeutics Global Market Report 2021 covers antisense & RNAi therapeutics market drivers, antisense & RNAi therapeutics market trends, antisense & RNAi therapeutics market growth rate, antisense & RNAi therapeutics market major players, player-adopted strategies in the market, and antisense & RNAi therapeutics market size.The global antisense & RNAi therapeutics market is expected to grow from $1.11 billion in 2020 to $1.2 billion in 2021 at a compound annual growth rate (CAGR) of 8.1%.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.
